Peran Brakhiterapi pada Kanker Serviks

Oleh :

dr.David Andi Wijaya, Sp.Onk.Rad

Brakhiterapi merupakan komponen penting dalam penatalaksanaan kanker serviks. Pemberian brakhiterapi bertujuan sebagai boost (tambahan dosis) pada tumor gross, sehingga mampu meningkatkan kontrol perjalanan penyakit dan kesintasan pasien. Brakhiterapi merupakan bagian dari radioterapi yang menempatkan sumber radioaktif pada jarak sangat dekat dengan tumor.[1-6]

Tujuan Brakhiterapi pada Kanker Serviks

Pemberian radiasi eksternal yang dilanjutkan dengan brakhiterapi merupakan terapi standar kanker serviks, terutama pada kasus lanjut lokal. Tujuan radioterapi eksternal adalah mencakupi dosis radiasi pada tumor primer dan memberikan ekstensi radiasi hingga ke parametrium dan KGB regional. Sementara itu, tujuan brakhiterapi untuk mencapai eskalasi dosis pada tumor lokal.[7]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Kamrava M,. Banerjee R. Brachytherapy in the treatment of cervical cancer: a review. Int. J. Womens. Health, p. 555, May 2014, doi: 10.2147/IJWH.S46247.
2. Lanciano RM., Won M., et al. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: A final report of the 1973 and 1978 patterns of care studies. Int. J. Radiat. Oncol., vol. 20, no. 4, pp. 667–676, Apr. 1991, doi: 10.1016/0360-3016(91)90007-Q.
3. Hanks GE., Herring DF., Kramer S. Patterns of care outcome studies results of the national practice in cancer of the cervix. Cancer, vol. 51, no. 5, pp. 959–967, Mar. 1983.
4. Coia L., Won M., et al. The patterns of care outcome study for cancer of the uterine cervix results of the second national practice survey. Cancer, vol. 66, no. 12, pp. 2451–2456, Dec. 1990,
5. Montana GS., Martz KL., Hanks GE. Patterns and sites of failure in cervix cancer treated in the U.S.A. in 1978. Int. J. Radiat. Oncol., vol. 20, no. 1, pp. 87–93, Jan. 1991, doi: 10.1016/0360-3016(91)90142-Q.
6. Logsdon MD,. Eifel PJ. FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int. J. Radiat. Oncol., vol. 43, no. 4, pp. 763–775, Mar. 1999, doi: 10.1016/S0360-3016(98)00482-9.
7. Shaili Aggarwal N., et al. NCCN Guidelines Version 1.2024 Cervical Cancer. 2023, Accessed: Sep. 28, 2023. https://www.nccn.org/home/member-.
8. Karlsson J., Dreifaldt AC., et al. Differences in outcome for cervical cancer patients treated with or without brachytherapy. Brachytherapy, vol. 16, no. 1, pp. 133–140, Jan. 2017, doi: 10.1016/j.brachy.2016.09.011.
9. Yu XL., et al. Role of brachytherapy in post-operative cervical cancer patients with risk factors other than positive stump. Brachytherapy, vol. 22, no. 2, pp. 166–173, Mar. 2023, doi: 10.1016/j.brachy.2022.10.002.
10. Chino J., et al. Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract. Radiat. Oncol., vol. 10, no. 4, pp. 220–234, Jul. 2020, doi: 10.1016/j.prro.2020.04.002.
11. Escande A., et al. Preoperative image-guided brachytherapy in early stage cervical cancers. Radiother. Oncol., vol. 120, no. 3, pp. 455–459, Sep. 2016, doi: 10.1016/j.radonc.2016.07.003.
12. Vieira-Serna S., et al. Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis. Gynecol. Oncol., vol. 169, pp. 4–11, Feb. 2023, doi: 10.1016/j.ygyno.2022.11.009.
13. Shen Z., Qu A., et al. Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review. Curr. Oncol., vol. 29, no. 8, pp. 5262–5277, Jul. 2022, doi: 10.3390/curroncol29080418.
14. Kozai Y., et al. High-dose-rate intracavitary brachytherapy for recurrent cervical cancer in the vaginal stump after hysterectomy. Nagoya J. Med. Sci., vol. 81, no. 3, pp. 351–358, Aug. 2019, doi: 10.18999/nagjms.81.3.351.
15. Ren X., et al. Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: A single institution experience. Front. Oncol., vol. 12, Jul. 2022, doi: 10.3389/fonc.2022.943703.
16. Viswanathan AN., et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy. Brachytherapy, vol. 11, no. 1, pp. 47–52, Jan. 2012, doi: 10.1016/j.brachy.2011.07.002.
17. Mahantshetty U., et al. Indian Brachytherapy Society Guidelines for radiotherapeutic management of cervical cancer with special emphasis on high-dose-rate brachytherapy. J. Contemp. Brachytherapy, vol. 11, no. 4, pp. 293–306, 2019, doi: 10.5114/jcb.2019.87406.
18. Pötter R., et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother. Oncol., vol. 78, no. 1, pp. 67–77, Jan. 2006, doi: 10.1016/j.radonc.2005.11.014.
19. Haie-Meder C., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group☆ (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother. Oncol., vol. 74, no. 3, pp. 235–245, Mar. 2005, doi: 10.1016/j.radonc.2004.12.015.
20. Pötter R. et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother. Oncol., vol. 100, no. 1, pp. 116–123, Jul. 2011, doi: 10.1016/j.radonc.2011.07.012.
21. Korenaga TRK., et al. Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer. Gynecol. Oncol., vol. 164, no. 2, pp. 348–356, Feb. 2022, doi: 10.1016/j.ygyno.2021.11.015.
22. Kim RY., Salter MM., Shingleton HM. Adjuvant postoperative radiation therapy following radical hysterectomy in stage ib ca of the cervix—analysis of treatment failure,” Int. J. Radiat. Oncol., vol. 14, no. 3, pp. 445–449, Mar. 1988, doi: 10.1016/0360-3016(88)90258-1.
23. Small W., et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy, vol. 11, no. 1, pp. 58–67, Jan. 2012, doi: 10.1016/j.brachy.2011.08.005.
24. Sedlis A., Bundy BN., et al. A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study,” Gynecol. Oncol., vol. 73, no. 2, pp. 177–183, May 1999, doi: 10.1006/gyno.1999.5387.
25. Cibula D., et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int. J. Gynecol. Cancer, vol. 28, no. 4, pp. 641–655, May 2018, doi: 10.1097/IGC.0000000000001216.
26. Scanderbeg DJ., Yashar C., et al. Development, implementation, and associated challenges of a new HDR brachytherapy program. Brachytherapy, vol. 19, no. 6, pp. 874–880, Nov. 2020, doi: 10.1016/j.brachy.2020.08.018.

Masuk atau Daftar

Nomor Ponsel Sudah Terdaftar

Masuk dengan Email

Masuk dengan Email

Masuk dengan Facebook

Masuk atau Daftar

Referensi

Artikel Terkait